- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Talis Biomedical Corporation is a medical devices business based in the US. Talis Biomedical Corporation shares (TLIS) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $1.70 – a decrease of 7.61% over the previous week. Talis Biomedical Corporation employs 99 staff and has a trailing 12-month revenue of around $408,000.
What's in this guide?
- TLIS shares summary
- Compare share dealing platforms
- Is TLIS stock a buy or sell?
- Stock performance over time
- Can I short TLIS shares?
- Talis Biomedical Corporation's financials
- How volatile are TLIS shares?
- Does Talis Biomedical Corporation pay a dividend?
- Have TLIS shares ever split?
- Other common questions
Our top picks for where to buy Talis Biomedical stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
How to buy Talis Biomedical Corporation stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – TLIS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Talis Biomedical Corporation stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Talis Biomedical Corporation stock price (PINK: TLIS)
Use our graph to track the performance of TLIS stocks over time.Talis Biomedical Corporation shares at a glance
Latest market close | $1.70 |
---|---|
52-week range | $1.37 - $9.60 |
50-day moving average | $1.74 |
200-day moving average | $5.74 |
Wall St. target price | $5.00 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-28.02 |
Talis Biomedical Corporation price performance over time
Historical closes compared with the close of $1.7275 from 2024-12-20
1 week (2024-12-17) | -6.11% |
---|---|
1 month (2024-11-22) | 2.22% |
3 months (2024-09-24) | -14.05% |
6 months (2024-06-24) | -79.77% |
1 year (2023-12-22) | -79.06% |
---|---|
2 years (2022-12-23) | -76.01% |
3 years (2021-12-23) | 63.9 |
5 years (2019-12-20) | N/A |
Talis Biomedical Corporation financials
Revenue TTM | $408,000 |
---|---|
Gross profit TTM | $-149,398,000 |
Return on assets TTM | -29.59% |
Return on equity TTM | -70.48% |
Profit margin | 0% |
Book value | $26.68 |
Market Capitalization | $3.4 million |
TTM: trailing 12 months
Talis Biomedical Corporation share dividends
We're not expecting Talis Biomedical Corporation to pay a dividend over the next 12 months.
You may also wish to consider:
Have Talis Biomedical Corporation's shares ever split?
Talis Biomedical Corporation's shares were split on a 1:15 basis on 5 July 2023 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Talis Biomedical Corporation shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Talis Biomedical Corporation shares which in turn could have impacted Talis Biomedical Corporation's share price.
Talis Biomedical Corporation share price volatility
Over the last 12 months, Talis Biomedical Corporation's shares have ranged in value from as little as $1.37 up to $9.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Talis Biomedical Corporation's is 1.561. This would suggest that Talis Biomedical Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Talis Biomedical Corporation's beta into context you can compare it against those of similar companies.
- Geron Corporation (GERN.US): 0.515
- Rigel Pharmaceuticals (RIGL.US): 0.953
- FibroGen (FGEN.US): 0.726
Talis Biomedical Corporation overview
Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois. .
Frequently asked questions
What percentage of Talis Biomedical Corporation is owned by insiders or institutions?Currently 8.306% of Talis Biomedical Corporation shares are held by insiders and 41.988% by institutions. How many people work for Talis Biomedical Corporation?
Latest data suggests 99 work at Talis Biomedical Corporation. When does the fiscal year end for Talis Biomedical Corporation?
Talis Biomedical Corporation's fiscal year ends in December. Where is Talis Biomedical Corporation based?
Talis Biomedical Corporation's address is: 1375 West Fulton Market, Chicago, IL, United States, 60607 What is Talis Biomedical Corporation's ISIN number?
Talis Biomedical Corporation's international securities identification number is: US87424L1089
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question